Lombard Medical Technologies PLC Adjournment of Court Hearing (7909E)
April 14 2014 - 11:09AM
UK Regulatory
TIDMLMT
RNS Number : 7909E
Lombard Medical Technologies PLC
14 April 2014
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR
INDIRECTLY, IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION
IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
Lombard Medical Technologies PLC
("Lombard Medical", or "the Company")
Adjournment of Court Hearing
London, UK, 14 April, 2014 - On 26 February 2014, Lombard
Medical (AIM: LMT), published a circular setting out the Board of
Directors' recommendations to, inter alia, reorganise the Lombard
Medical Group pursuant to a Court approved scheme of arrangement
(the "Scheme") for Lombard Medical to become a directly-owned
subsidiary of Lombard Medical, Inc ("LM, Inc").
On 18 March 2014, the Company announced that the Court Meeting
held on that day approved the proposed Scheme as well as a revision
to the indicative timetable published in the Circular.
On 11 April 2014 the Company announced a further revision to the
indicative timetable published in the Circular, as a result of the
timetable of the IPO of LM, Inc shares on the NASDAQ Global Market
being extended due to current adverse US stock market
conditions.
A Court Hearing was held today and the Court granted an
adjournment until 29 April 2014.
The timetable is currently being reviewed and the Company will
notify shareholders of the revised timetable, including details of
the adjourned Court Hearing, in due course through a Regulatory
Information Service and by notice on the Company's website.
This press release and the information it contains is not for
publication or distribution, directly or indirectly, in or into the
United States. This press release is not intended to, and does not
constitute an offer to sell or the solicitation of an offer to buy
any securities, nor shall there be any sale of the securities
referred to herein in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration,
exemption from registration or qualification under the securities
laws of any such jurisdiction.
-Ends-
For further information:
Lombard Medical Technologies PLC Tel: +44 (0)1235 750 800
Simon Hubbert, Chief Executive
Officer
Ian Ardill, Chief Financial Officer
Canaccord Genuity Limited (Nomad) Tel: +44 (0)20 7523 8000
Lucy Tilley / Tim Redfern / Henry
Fitzgerald O'Connor / Dr Julian
Feneley
FTI Consulting (UK) Tel: +44 (0) 203 727 1000
Simon Conway / Stephanie Cuthbert
/ Victoria Foster Mitchell
About Abdominal Aortic Aneurysms ("AAA")
AAAs are a balloon-like enlargement of the aorta which, if left
untreated, may rupture and cause death. Approximately 4.5 million
people are living with AAAs in the developed world and each year
over 500,000 new cases are diagnosed. In the US, aortic aneurysm
disease is among the leading causes of death and it is estimated
that 1.7 million people over the age of 55 have an abdominal aortic
aneurysm.
About Lombard Medical
Lombard Medical Technologies PLC (AIM:LMT) is a medical device
company focused on device solutions for the $1.4 billion per annum
abdominal aortic aneurysm repair market. The Company's lead
product, Aorfix(TM), is an endovascular stent graft which has been
specifically designed to solve the problems that exist in treating
complex tortuous anatomy, which is often present in advanced AAA
disease. Aorfix is the only stent graft approved by the US FDA for
AAA neck angulations of up to 90 degrees and is currently being
commercialized worldwide. Aorfix is the first AAA stent graft not
of US origin to gain US FDA approval. The Company is headquartered
in Oxfordshire, England with US operations in Irvine, CA.
Further background on the Company can be found at
www.lombardmedical.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCGGURACUPCGWC
Lombard Medical Technologies (LSE:LMT)
Historical Stock Chart
From Nov 2024 to Dec 2024
Lombard Medical Technologies (LSE:LMT)
Historical Stock Chart
From Dec 2023 to Dec 2024